CMS (Centers for Medicare & Medicaid Services). 2013. Forecast summary. Major findings for national health expenditures: 2012–2022. (accessed September 20, 2013).

Davis, P. B., U. Yasothan, and P. Kirkpatrick. 2012. Ivacaftor. Nature Reviews Drug Discovery 11(5):349–350.

Dequeker, E., M. J. Ligtenberg, S. Vander Borght, and J. H. van Krieken. 2011. Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: Development and evaluation of quality by a European external quality assessment scheme. Virchows Archiv 459(2):155–160.

DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. 2003. The price of innovation: New estimates of drug development costs. Journal of Health Economics 22(2):151–185.

Eichler, H. G., B. Bloechl-Daum, E. Abadie, D. Barnett, F. Konig, and S. Pearson. 2010. Relative efficacy of drugs: An emerging issue between regulatory agencies and third-party payers. Nature Reviews Drug Discovery 9(4):277–291.

FDA (U.S. Food and Drug Administration). 2011. Guidance for industry and Food and Drug Administration Staff—in vitro companion diagnostic devices. (accessed October 24, 2013).

Gonzalez de Castro, D., B. Angulo, B. Gomez, D. Mair, R. Martinez, A. Suarez-Gauthier, F. Shieh, M. Velez, V. H. Brophy, H. J. Lawrence, and F. Lopez-Rios. 2012. A comparison of three methods for detecting kras mutations in formalin-fixed colorectal cancer specimens. British Journal of Cancer 107(2):345–351.

Halait, H., K. Demartin, S. Shah, S. Soviero, R. Langland, S. Cheng, G. Hillman, L. Wu, and H. J. Lawrence. 2012. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagnostic Molecular Pathology 21(1):1–8.

Longshore, J. W., H. Amidon, H. N. Todd, J. Fu, M. Christensen, J. Tsai, G. Hillman, H. Halait, F. Shieh, J. Lawrence, E. Lipford. 2012. A methods comparison analysis of the Roche cobas 4800 BRAF V600 mutation test and the Qiagen BRAF RGQ PCR kit on melanoma specimens with challenging attributes. Journal of Molecular Diagnostics 14(6):716.

Moore, M. W., D. Babu, and P. D. Cotter. 2012. Challenges in the co-development of companion diagnostics. Personalized Medicine 9(5):485–496.

Quinn, B. 2010. Payers and the assessment of clinical utility for companion diagnostics. Clinical Pharmacology & Therapeutics 88(6):751–754.

van Krieken, J. H., N. Normanno, F. Blackhall, E. Boone, G. Botti, F. Carneiro, I. Celik, F. Ciardiello, I. A. Cree, Z. C. Deans, A. Edsjo, P. J. Groenen, O. Kamarainen, H. H. Kreipe, M. J. Ligtenberg, A. Marchetti, S. Murray, F. J. Opdam, S. D. Patterson, S. Patton, C. Pinto, E. Rouleau, E. Schuuring, S. Sterck, M. Taron, S. Tejpar, W. Timens, E. Thunnissen, P. M. van de Ven, A. G. Siebers, and E. Dequeker. 2013. Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Archiv 462(1):27–37.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement